Opportunities for Point-of-Care Diagnostics in Outpatient Pediatric Centers to Influence Antibiotic Prescribing Patterns

Article

Sponsored Content

Supplements And Featured PublicationsOpportunities for Point-of-Care Diagnostics in Outpatient Pediatric Centers to Influence Antibiotic Prescribing Patterns

This article addresses factors that contribute to inappropriate antibiotic prescribing patterns and the performance and impact of a CLIA-waived, point-of-care respiratory polymerase chain reaction (PCR) panel in a pediatric clinic.

Download PDF

Articles in this issue
Opportunities for Point-of-Care Diagnostics in Outpatient Pediatric Centers to Influence Antibiotic Prescribing Patterns
Recent Videos
Diet, mental health, and pediatric nutrition, with Colleen Sloan, PA-C, RDN
Victor Carrion, MD
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jennifer Soung, MD reacts to FDA approval of roflumilast foam 0.3%
Supporting mental health in pediatric primary care with Victor Carrion, MD
Discussing social media and potential nutrition impacts with Colleen Sloan, PA-C, RDN
Jenna Marcovitz, MA explains how music therapy helps in pediatric care
Related Content
First infant enrolled in trial of roflumilast 0.05% for atopic dermatitis in infants | | Image Credit: © Dinko - © Dinko- stock.adobe.com.

First infant enrolled in trial of roflumilast cream, 0.05% for atopic dermatitis in infants

Joshua Fitch, Senior Editor
June 10th 2025
Article

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA approves clesrovimab to protect infants during first RSV season | Image Credit: Contemporary Pediatrics

FDA approves clesrovimab to protect infants during first RSV season

Joshua Fitch, Senior Editor
June 9th 2025
Article

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia | Image Credit: © lexiconimages - © lexiconimages - stock.adobe.com.

Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia

Joshua Fitch, Senior Editor
June 9th 2025
Article

The combination therapy yielded boosted treatment benefits of navepegritide, including improvement in mean ACH Z-score and mean annualized growth.

Weekly review: MMR vaccination decline, more COVID-19 vaccine changes, and more

Weekly review: MMR vaccination decline, more COVID-19 vaccine changes, and more

Joshua Fitch, Senior Editor
June 6th 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

© 2025 MJH Life Sciences

All rights reserved.